Augmedix Delivers 40 percent Revenue Growth for First Quarter of 2024
| AUGXDelisted Stock | USD 2.35 0.00 0.00% |
Slightly above 56% of Augmedix's investor base is looking to short. The analysis of current outlook of investing in Augmedix suggests that many traders are alarmed regarding Augmedix's prospects. Augmedix's investing sentiment can be driven by a variety of factors including economic data, Augmedix's earnings reports, geopolitical events, and overall market trends.
Augmedix |
SAN FRANCISCO, May 13, 2024 -- Augmedix , a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended March 31, 2024. Augmedix delivered in-line first quarter performance, with 40 percent revenue growth, 143 percent net revenue retention and 47.1 percent gross margins, commented Manny Krakaris, Augmedix CEO. We are confident about our positioning within the medical documentation market, and expect to report continued g
Read at finance.yahoo.com
 |
Augmedix Fundamental Analysis
We analyze Augmedix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Augmedix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Augmedix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Augmedix is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Augmedix Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Augmedix stock to make a market-neutral strategy. Peer analysis of Augmedix could also be used in its relative valuation, which is a method of valuing Augmedix by comparing valuation metrics with similar companies.
Peers
Augmedix Related Equities
| ACON | Aclarion | 5.88 | ||||
| ELEV | Elevation Oncology | 3.23 | ||||
| DRMA | Dermata Therapeutics | 2.73 | ||||
| INAB | In8bio | 3.23 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Augmedix Stock
If you are still planning to invest in Augmedix check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Augmedix's history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |